Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know

Tenet Healthcare (THC) is trending on Zacks.com, with shares up 11.5% in the past month, outperforming the S&P 500. Positive earnings estimate revisions have contributed to a Zacks Rank #2 (Buy), with current quarter EPS expected to increase 22.9% year-over-year to $2.84 and fiscal year EPS expected to rise 7.1% to $12.72; the company also has a Value Style Score of A, indicating it may be undervalued relative to its peers.

Analysis

Tenet Healthcare Corporation (THC) has recently attracted significant investor interest, reflected in its shares returning +11.5% over the past month, outpacing both the Zacks S&P 500 composite's +5.2% gain and the Zacks Medical - Hospital industry's +9.7% rise. This performance is substantially underpinned by positive revisions in earnings estimates. For the current quarter, Tenet is expected to report earnings of $2.84 per share, a +22.9% increase year-over-year, with the Zacks Consensus Estimate having risen +2% in the last 30 days. The consensus EPS estimate for the current fiscal year stands at $12.72, indicating a +7.1% year-over-year growth, and has seen a +0.5% upward revision recently. For the next fiscal year, EPS is projected at $13.61, a +7% increase, with a +0.3% revision in the past month. These positive estimate revisions have contributed to Tenet securing a Zacks Rank #2 (Buy). Projected revenue growth appears more moderate, with consensus sales estimates at $5.15 billion for the current quarter (+0.9% YoY), $20.9 billion for the current fiscal year (+1.1% YoY), and $21.93 billion for the next fiscal year (+5% YoY). In its last reported quarter, Tenet's revenues were $5.22 billion, a -2.7% year-over-year decrease, yet this figure represented a +1.64% surprise over consensus. More impressively, EPS for that period was $4.36, a +40.19% surprise and a significant increase from $3.22 a year ago, marking the fourth consecutive quarter of EPS estimate beats. The company also holds a Zacks Value Style Score of 'A', indicating it may be trading at a discount relative to its peers.

Key Decisions for Investors

• Given the strong positive earnings estimate revisions, consistent EPS outperformance, and a Zacks Rank #2 (Buy), investors could consider Tenet Healthcare for potential near-term market outperformance.
• The stock's 'A' grade for value suggests potential for further appreciation despite the recent +11.5% share price increase, but investors should closely monitor upcoming revenue figures given the modest growth projections and the slight year-over-year decline in the last reported quarter.
• Continued vigilance on the sustainability of strong EPS growth, particularly in the context of relatively flat near-term revenue forecasts, is advisable when evaluating long-term positions.